Trial Profile
Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Dec 2019
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Acronyms RIG
- 16 Nov 2019 Status changed from recruiting to discontinued.
- 23 Nov 2018 Planned End Date changed from 1 Jan 2021 to 1 Mar 2023.
- 23 Nov 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2022.